Bolt Biotherapeutics (BOLT) director receives 5,000 stock options at $4.43 strike

Rhea-AI Filing Summary

Bolt Biotherapeutics director Nicole Onetto received a grant of stock options for 5,000 shares of common stock. The options have an exercise price of $4.43 per share and were awarded as a compensation-related grant, not an open-market purchase.

The filing shows she now holds stock options covering 5,000 shares directly after this transaction. These options vest on the earlier of June 9, 2027 or the day immediately before Bolt Biotherapeutics’ next annual stockholder meeting, subject to her continued service. The options will vest in full if there is a change in control of the company.

Insights

Equity compensation analyst

Routine director stock option grant with time-based and change-in-control vesting.

Director Nicole Onetto received stock options on June 10, 2026 for 5,000 shares of Bolt Biotherapeutics common stock at an exercise price of $4.43 per share. The transaction is coded as a grant/award acquisition, indicating standard equity compensation rather than a market trade.

The options vest on the earlier of June 9, 2027 or the day before the next annual stockholder meeting, contingent on continuous service, with full vesting upon a change in control. This structure aligns director incentives with company performance while providing protection if ownership changes. From an investor standpoint, this is a routine, low-dilution governance practice.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider ONETTO NICOLE

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	5,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 5,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 5,000 shares Exercise price: $4.43 per share Post-grant option holdings: 5,000 shares +2 more

5 metrics

Option grant size 5,000 shares Stock options for common stock granted to director

Exercise price $4.43 per share Strike price for newly granted stock options

Post-grant option holdings 5,000 shares Total underlying shares following this derivative transaction

Option expiration June 9, 2036 Expiration date of the stock option award

Latest vesting date June 9, 2027 Latest scheduled vesting date absent earlier annual meeting or change in control

Key Terms

Stock Option (Right to Buy), exercise price, change in control, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price": "4.4300""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

change in control financial

"the option will vest in full upon a change in control of the Issuer"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

annual meeting of stockholders regulatory

"the day immediately prior to the next annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ONETTO NICOLE

(Last) (First) (Middle)

C/O BOLT BIOTHERAPEUTICS, INC.

900 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bolt Biotherapeutics, Inc. [ BOLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.43	06/10/2026		A		5,000		(1)	06/09/2036	Common Stock	5,000	$0	5,000	D

Explanation of Responses:

1. The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.

	/s/ William P. Quinn, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Bolt Biotherapeutics (BOLT) director Nicole Onetto receive in this Form 4?

Nicole Onetto received a grant of stock options for 5,000 shares of Bolt Biotherapeutics common stock. These options were awarded as compensation, not purchased on the open market, and give her the right to buy shares at a fixed exercise price of $4.43 per share.

What is the exercise price of the Bolt Biotherapeutics (BOLT) stock options granted to Nicole Onetto?

The stock options granted to Nicole Onetto have an exercise price of $4.43 per share. This means she can buy up to 5,000 Bolt Biotherapeutics common shares at $4.43, regardless of future market price, once the options vest under the specified schedule.

When do Nicole Onetto’s Bolt Biotherapeutics (BOLT) stock options vest?

Nicole Onetto’s options vest on the earlier of June 9, 2027, or the day immediately before the next annual stockholder meeting. Vesting is conditioned on her continuous service, and the options are designed to reward ongoing board involvement over time.

What happens to Nicole Onetto’s Bolt Biotherapeutics (BOLT) options if there is a change in control?

If there is a change in control of Bolt Biotherapeutics, Nicole Onetto’s stock options will vest in full. This acceleration provision protects the director’s equity award if the company is sold or undergoes a similar control transaction before normal vesting occurs.

How many Bolt Biotherapeutics (BOLT) options does Nicole Onetto hold after this Form 4 transaction?

After this transaction, Nicole Onetto holds stock options covering 5,000 shares of Bolt Biotherapeutics common stock directly. The Form 4 indicates these options were newly granted, and the total derivative holdings reported following the grant equal 5,000 underlying shares.

Is Nicole Onetto buying or selling Bolt Biotherapeutics (BOLT) shares in this Form 4?

Nicole Onetto is not buying or selling shares on the market in this filing. Instead, she is receiving a grant of stock options as a compensation award, giving her the right to purchase 5,000 shares in the future at a fixed $4.43 exercise price.